Physician profile
Brian Lin
NPI 1174051940
$1,760.76
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,415 · 2020: $240 · 2021: $106.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $946.01 | 2019-2020 | |
| Abbvie INC. | $246.86 | 2019 | |
| Gilead Sciences, INC. | $123.62 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $121.85 | 2019 | |
| Pfizer INC. | $114.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $105.97 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $102.45 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.